Article Page

Abstract

We study the relation between hidden variables theories and quantum computation. We discuss an inconsistency between a hidden variables theory and controllability of quantum computation. To derive the inconsistency, we use the maximum value of the square of an expected value. We propose a solution of the problem by using new hidden variables theory. Also we discuss an inconsistency between hidden variables theories and the double-slit experiment as the most basic experiment in quantum mechanics. This experiment can be an easy detector to Pauli observable. We cannot accept hidden variables theories to simulate the double-slit experiment in a specific case. Hidden variables theories may not depicture quantum detector. This is a quantum measurement theoretical profound problem whether Hidden Variables Theories can meet Quantum Computation for high-resolution refinement and binding affinity estimation of inhibitors of CGQMCTVWCSSGC targeted conserved peptide substitution on mimetic pharmaco-structures with antagonizing VEGFR-3-mediated oncogenic effects?

Keywords

Hidden Variables Theories; Quantum Computation; high-resolution refinement; binding affinity estimations; inhibitors; CGQMCTVWCSSGC targeted; conserved peptide; substitution mimetic; pharmaco-structures; antagonizing VEGFR-3-mediated; oncogenic effects, Quantum Computer, Quantum Information Theory, Quantum Non Locality, Subject Areas: Applied Physics.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Can Hidden Variables Theories Meet Quantum Computation for high-resolution refinement and binding affinity estimation of inhibitors of CGQMCTVWCSSGC targeted conserved peptide substitution on mimetic pharmaco-structures with antagonizing VEGFR-3-mediated oncogenic effects?

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available